Indian Study Finds Vildagliptin SR Effective and Safe in Type 2 Diabetes Patients Uncontrolled on Metformin: PRIME-Vilda Trial Dr. Garima Soni30 Oct 2025 12:11 PM ISTVildagliptin SR 100 mg once daily has been shown to be effective and safe in improving glycemic control in Indian T2DM patients in India not...
Advancements in Antifungal Treatment: Insights from In vitro Trials with Selenium Sulfide Dr. Kamal Kant Kohli30 Oct 2025 11:15 AM ISTFungal infections represent a significant challenge in human medicine. With increasing resistance to conventional antifungal therapies and the...
The Betami-Danblock Trial: Randomized Discontinuation Of Beta-Blockers After Myocardial Infarction Prem Aggarwal28 Oct 2025 12:30 PM ISTBETAMI-DANBLOCK evaluates whether discontinuation of beta-blockers after MI is safe in patients with preserved or mildly reduced LVEF (>40%) in the...
Reperfusion Therapy for STEMI in LMICs: A Clinical Consensus Discussion with Dr Thomas Alexander Deeksha Bhandari28 Oct 2025 12:15 PM ISTIn this video, renowned cardiologist Dr Thomas Alexander, Senior Interventional Cardiologist and Head of the Division of Cardiology at Kovai Medical...
Importance of Identifying High-Risk Node-Positive Patients in EBC Medical Dialogues Team15 Oct 2025 11:45 AM ISTIn this video a clinical case is presented of a 54-year-old postmenopausal woman with a family history of HR+/HER2- breast cancer presented with a...
EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress Deeksha Bhandari14 Oct 2025 12:51 PM ISTEvery 12 minutes, a person with diabetes thinks about their condition. For many, this constant burden leads to diabetes distress-a state of...
PRO-ACT Study Compares Topical Minoxidil 5% with PRCT vs Plain Minoxidil 5% in Androgenetic Alopecia-Combination Shows Superior Efficacy Dr. Garima Soni14 Oct 2025 12:31 PM ISTA Novel formulation of Minoxidil 5% and PRCT (Procapil, Redensyl, Caffeine, and Transcutol) has emerged superior in effectiveness, tolerability, and...
DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings Deeksha Bhandari13 Oct 2025 12:30 PM ISTDAa-ViNCI study which analyzed the efficacy, safety and practice of pattern of Vildagliptin 100mg and dapagliflozin 10mg in cardiology practice. ...
India's Unique CV Risk Profile: How to Decode the Role of Aspirin? Dr. Ajay U. Mahajan7 Oct 2025 11:47 AM ISTCardiovascular disease remains one of the dominant non-communicable causes of death in India, contributing substantially to premature morbidity and...
Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest DAa-ViNCI Study Dr. Bhumika Maikhuri6 Oct 2025 12:22 PM ISTIn a new study, fixed-dose combination (FDC) of vildagliptin and dapagliflozin demonstrated substantial efficacy and good tolerability in managing...
Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial Deeksha Bhandari3 Oct 2025 12:09 PM ISTSURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of...
Negligence vs Misconduct: Where Do Medical Councils Draw the Line? Prem Aggarwal3 Oct 2025 11:00 AM ISTMedical councils play a crucial role in upholding the dignity and ethics of the medical profession. However, an important debate surrounds the scope...
